(Street)
NEW YORK

(City)

NY

(State)

1. Name and Address of Reporting Person\*

10020

(Zip)

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvaoriington, D.O. 20

<b>STATEMENT</b>	<b>OF CHANGES I</b>	N BENEFICIAL	OWNERSHIP

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	1(5).			riicu							company Act o		7 1554							
1. Name and Address of Reporting Person*  COUCHMAN JONATHAN			EN	2. Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS, INC. [ ENZN ]										Relationship of Reporting Person(s) to Issuer (Check all applicable)      Director X 10% Owner      Officer (give title Other (specify)						
(Last) (First) (Middle) 600 FIFTH AVENUE 2ND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 03/13/2020															
(Street) NEW YORK NY 10020					4. If Amendment, Date of Original Filed (Month/Day/Year) 03/27/2020									6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  X Form filed by More than One Reporting Person						
(City)	(St	ate)	(Zip)																	
		Tabl	e I - N	on-Deriva	tive S	Secu	rities	Acc	quire	d, Di	sposed of	, or E	Benef	icia	lly Own	ed				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		·	3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr 5)		ed (A) o	or and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) 01 (D)	Pric	е	Transact (Instr. 3 a	ion(s)			, ,	
Common	ommon Stock, \$0.01 par value <sup>(1)</sup> 03		03/13/20	)20				P		19,709	A	\$0.	135	1,594,232		I		By Xstelos Corp. <sup>(2)</sup>		
Common	Stock, \$0.	01 par value <sup>(1)</sup>		03/23/20	20				P		2,678	A	\$0	.14	2,9	)28		I	By Myrexis, Inc. <sup>(4)</sup>	
Common	Stock, \$0.0	01 par value <sup>(1)</sup>		03/25/2020		20			P		469,551	A	\$0	.14	472,479			I	By Myrexis, Inc. <sup>(4)</sup>	
Common Stock, \$0.01 par value <sup>(1)</sup>		03/26/2020					P		160,785	A	\$0	.14	633,264		I		By Myrexis, Inc. <sup>(4)</sup>			
Common	Stock, \$0.	01 par value <sup>(1)</sup>													4,717	7,666		D		
Common Stock, \$0.01 par value <sup>(1)</sup>														400,	,000		I	By Couchman Family Fund <sup>(3)</sup>		
		Та	able II								posed of, convertib				/ Owne	d				
1. Title of Derivative Conversion Or Exercise (Instr. 3)  2. Conversion Date (Month/Day/Year Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		te Exe	rcisable and	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8 D S (I	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reporter Transact (Instr. 4)	re es ally eg d tion(s)	10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficia Ownershi ect (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amou or Numb of Share	er						
		f Reporting Person	n*																	
(Last) 600 FIFT 2ND FL0	TH AVENU OOR	(First) JE	1)	Middle)																

Couchman Family Fund							
(Last) 600 FIFTH AVEN 2ND FLOOR	(First) NUE	(Middle)					
(Street) NEW YORK	NY	10020					
(City)	(State)	(Zip)					
Name and Address of Reporting Person*     Xstelos Corp.							
(Last) (First) (Middle) 600 FIFTH AVENUE 2ND FLOOR							
(Street) NEW YORK	NY	10020					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  Myrexis, Inc.							
(Last) (First) (Middle) 600 FIFTH AVENUE, 2ND FLOOR							
(Street) NEW YORK	NY	10020					
(City)	(State)	(Zip)					

## **Explanation of Responses:**

- 1. This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis" and, together with Mr. Couchman, the Foundation and Xstelos, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
- 2. Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
- 3. Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
- 4. Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.

## Remarks:

This amended Form 4 is filed on behalf of the Reporting Persons because as of the original filing date, Myrexis did not have the necessary SEC filing codes. Myrexis has since obtained the necessary filing codes and the Reporting Persons are filing this amendment accordingly.

> /s/ Jonathan Couchman 03/31/2020 Couchman Family Fund; By: 03/31/2020 /s/ Jonathan Couchman, Trustee Xstelos Corp.; By: /s/ Jonathan Couchman, Chief 03/31/2020 **Executive Officer** Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive 03/31/2020

Officer

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.